This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Lipid complex amphotericin B, ABLC
Description: Abelcet is a lipid complex formulation of amphotericin B. Amphotericin B is a potent, broad spectrum, fungicidal drug for fighting fungal infections, limited only by its systemic toxicities. Amphotericin B binds to sterols, preferentially to the primary fungal cell membrane sterol, ergosterol. This binding disrupts osmotic integrity of the fungal membrane, resulting in leakage of intracellular potassium, magnesium, sugars, and metabolites and then cellular death. The mechanism of action is the same for all the preparations and is due to the intrinsic antifungal activity of Amphotericin B.
Elan and Enzon
Elan acquired Abelcet through its merger with The Liposome Company. Enzon announced in 2002 the signing of an agreement under which Enzon will acquire the North American rights to Abelcet from Elan Corporation. Enzon was to pay a total of $370 million in cash upon the closing of the deal, including an estimated $30 million for the manufacturing facility. Under the terms of the agreement, the $370 million may have been subject to certain price deductions at closing.
Elan and Zeneus
Apax Partners Funds announced in 2004 the closing of the acquisition of Elan Corporation's European Sales and marketing business for $120 million by Medeus Pharma Ltd. Medeus Pharma changed its name to Zeneus Pharma in September 2004.
Cephelon and Zeneus
In December 2005, Cephalon completed its acquisition of Zeneus Pharma.
Enzon and Sigma-Tau
In November 2009, Enzon Pharmaceuticals announced that it entered into a definitive agreement to sell...See full deal structure in Biomedtracker
Partners: Teva Pharmaceutical Industries Ltd. Enzon Pharmaceuticals, Inc.
Pink Sheet Product News: The Liposome Company
Additional information available to subscribers only: